Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Drug Standards Sought

by Rick Mullin
November 19, 2012 | A version of this story appeared in Volume 90, Issue 47

The European Fine Chemicals Group, a trade association, is calling for a global harmonization of regulations governing the manufacture of active pharmaceutical ingredients (APIs). The group hopes to “level the worldwide playing field” by ensuring that all pharmaceutical chemicals meet standards set by U.S. and European Union regulatory authorities. EFCG proposes a “mutual recognition agreement” under which regional regulators share inspection resources to avoid duplicating efforts in inspecting plants that manufacture APIs coming into Europe. The proposal was submitted late last month to the EU-U.S. High Level Regulatory Cooperation Forum, an initiative focused on regulatory liaison between the U.S. and Europe. EFCG argues that the EU’s recently enacted Falsified Medicines Directive, designed to minimize counterfeit medicines entering the EU, does not adequately address issues of general API quality. It points to illegal manufacturing of drug chemicals in Asia as the key threat.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.